160 related articles for article (PubMed ID: 37744345)
1. Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy.
Johansen AZ; Novitski SI; Hjaltelin JX; Theile S; Boisen MK; Brunak S; Madsen DH; Nielsen DL; Chen IM
Front Immunol; 2023; 14():1228907. PubMed ID: 37744345
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC).
Chen IM; Johansen JS; Theile S; Hjaltelin JX; Novitski SI; Brunak S; Hasselby JP; Willemoe GL; Lorentzen T; Madsen K; Jensen BV; Wilken EE; Geertsen P; Behrens C; Nolsoe C; Hermann KL; Svane IM; Nielsen D
J Clin Oncol; 2022 Sep; 40(27):3180-3189. PubMed ID: 35476508
[TBL] [Abstract][Full Text] [Related]
3. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
4. Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma.
Christensen TD; Maag E; Theile S; Madsen K; Lindgaard SC; Hasselby JP; Nielsen DL; Johansen JS; Chen IM
ESMO Open; 2024 Jun; 9(6):103489. PubMed ID: 38838501
[TBL] [Abstract][Full Text] [Related]
5. Chitooligosaccharides Improve the Efficacy of Checkpoint Inhibitors in a Mouse Model of Lung Cancer.
Johansen AZ; Carretta M; Thorseth ML; Khan S; Fjæstad KY; Brøchner CB; Linder H; Ankjærgaard C; Donia M; Chen I; Nielsen DL; Behrens CP; Madsen DH
Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631632
[TBL] [Abstract][Full Text] [Related]
6. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
Tarpgaard LS; Guren TK; Glimelius B; Christensen IJ; Pfeiffer P; Kure EH; Sorbye H; Ikdahl T; Yilmaz M; Johansen JS; Tveit KM
PLoS One; 2014; 9(2):e87746. PubMed ID: 24498368
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.
Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Bojesen SE; Pfeiffer P; Bjerregaard JK; Nielsen SE; Andersen F; Holländer NH; Yilmaz MK; Rasmussen LS; Johansen JS
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):176-184. PubMed ID: 31685562
[TBL] [Abstract][Full Text] [Related]
8. Prognostic utility of serum YKL-40 in patients with cervical cancer.
Roslind A; Palle C; Johansen JS; Christensen IJ; Nielsen HJ; Mosgaard BJ
Scand J Clin Lab Invest; 2020 Dec; 80(8):687-693. PubMed ID: 33186077
[TBL] [Abstract][Full Text] [Related]
9. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts.
Kornblit B; Hellemann D; Munthe-Fog L; Bonde J; Strøm JJ; Madsen HO; Johansen JS; Garred P
Immunobiology; 2013 Oct; 218(10):1227-34. PubMed ID: 23706599
[TBL] [Abstract][Full Text] [Related]
10. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
[TBL] [Abstract][Full Text] [Related]
11. YKL-40 tissue expression and plasma levels in patients with ovarian cancer.
Høgdall EV; Ringsholt M; Høgdall CK; Christensen IJ; Johansen JS; Kjaer SK; Blaakaer J; Ostenfeld-Møller L; Price PA; Christensen LH
BMC Cancer; 2009 Jan; 9():8. PubMed ID: 19134206
[TBL] [Abstract][Full Text] [Related]
12. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer.
Hermunen K; Soveri LM; Boisen MK; Mustonen HK; Dehlendorff C; Haglund CH; Johansen JS; Osterlund P
Acta Oncol; 2020 Dec; 59(12):1416-1423. PubMed ID: 32790589
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of YKL-40 as a prognostic factor in childhood acute lymphoblastic leukemia.
Rivas-Alarcón AA; Gómez-Gómez Y; Organista-Nava J; Jiménez-López MA; Rivera-Ramírez AB; Ibarra-Sierra E; Saavedra-Herrera MV; Illades-Aguiar B; Leyva-Vázquez MA
Mol Clin Oncol; 2021 Aug; 15(2):168. PubMed ID: 34194746
[TBL] [Abstract][Full Text] [Related]
14. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
[TBL] [Abstract][Full Text] [Related]
15. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of the proinflammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene (CHI3L1), and incident cardiovascular events.
Ridker PM; Chasman DI; Rose L; Loscalzo J; Elias JA
J Am Heart Assoc; 2014 Jun; 3(3):e000897. PubMed ID: 24958781
[TBL] [Abstract][Full Text] [Related]
17. Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.
Boisen MK; Holst CB; Consalvo N; Chinot OL; Johansen JS
Oncotarget; 2018 Jan; 9(6):6752-6762. PubMed ID: 29467925
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.
Schultz NA; Christensen IJ; Werner J; Giese N; Jensen BV; Larsen O; Bjerregaard JK; Pfeiffer P; Calatayud D; Nielsen SE; Yilmaz MK; Holländer NH; Wøjdemann M; Bojesen SE; Nielsen KR; Johansen JS
PLoS One; 2013; 8(6):e67059. PubMed ID: 23840582
[TBL] [Abstract][Full Text] [Related]
19. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients.
Wan G; Xiang L; Sun X; Wang X; Li H; Ge W; Cao F
Oncotarget; 2017 Jan; 8(3):5382-5391. PubMed ID: 28036271
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
Boisen MK; Madsen CV; Dehlendorff C; Jakobsen A; Johansen JS; Steffensen KD
Int J Gynecol Cancer; 2016 Oct; 26(8):1390-8. PubMed ID: 27648712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
